Fexuprazan

Jaqbo, a new P-CAB by Onconic Therapeutics, debuted in Korea's peptic ulcer market with modest sales of $380k, lagging behind rivals K-CAB and Fexuclue. Despite strategic partnerships and significant investment, Jaqbo faces an established market dominated by K-CAB and Fexuclue, with over 20 companies preparing to launch generic versions of Vicinti.

Daewoong Pharmaceutical presents microneedle-based drug delivery technologies at CPHI Worldwide 2024 in Milan, including the first commercial microneedle drug, CLOPAM®. The company also showcases innovations like a once-monthly Semaglutide injection for obesity and a patient-friendly colonoscopy preparation tablet.